Strategic insight from
the clinic to the boardroom
We provide strategic advisory services to pharmaceutical companies, diagnostic organizations, and health-tech teams navigating the intersection of clinical oncology, genomics, and evidence-based decision-making.
Built for organizations at the
cutting edge of oncology
Our advisory practice is structured around three client types, each with distinct strategic needs we are uniquely qualified to address.
Pharmaceutical & Biotech
Drug sponsors and clinical development teams seeking a practicing oncologist with direct HTA, market access, and real-world evidence experience. We have served on Canadian Drug Agency (CDA) pCODR and CCO funding committees and bring that fluency to your submissions.
- Clinical trial design and registry strategy
- Medical affairs and KOL engagement
- HTA submission strategy and gap analysis
- Launch readiness and treatment paradigm mapping
Diagnostics & Genomics
Diagnostic companies and NGS platform developers who need a clinical champion who understands both the assay and the treatment decision downstream. We help you build physician demand, clinical utility evidence, and pathway integration strategies.
- Clinical utility and actionability framing
- Companion diagnostic advisory and CDx pathway design
- Physician education strategy
- Integration into oncology treatment algorithms
Health-Tech & AI Startups
Engineering teams building clinical decision support, AI diagnostic tools, or digital health platforms who need a practicing oncologist to validate clinical logic, bridge the language gap with hospital systems, and de-risk regulatory and adoption pathways.
- Clinical validation and workflow integration
- AI model oversight and clinical safety review
- Physician advisory and go-to-market strategy
- Hospital and health system partnership navigation
What we bring to the table
Clinical Trial Strategy
Direct PI experience on international real-world registries including the FLEX trial. We help organizations design, implement, and extract maximum clinical utility from complex oncology trial programs.
Health Economics & Market Access
With direct experience serving on Canadian Drug Agency (CDA) pCODR and CCO funding committees, we provide strategic guidance on HTA submissions, reimbursement strategy, and translating clinical evidence into economic narratives that resonate with payers.
Genomic Integration
Helping diagnostic companies and therapeutic sponsors build clinical utility and physician demand around genomic assays by embedding them into actionable treatment pathways, from the lab report to the treatment decision.
Health-Tech Strategy
Guiding AI and software engineering teams on the development of rigorous, safe, and clinically-meaningful decision support tools. We bridge the language gap between technical teams and practicing oncologists, so you build the right thing.
Two engagement models,
designed for real partnerships
Advisory Board
A formal, ongoing advisory relationship. Ideal for companies seeking a practicing oncologist who can provide consistent clinical grounding to a product, platform, or program over time. Structured with defined meeting cadences, scope, and deliverables.
Project-Based
A defined-scope engagement with clear objectives, deliverables, and timeline. Ideal for organizations with a specific strategic question: a market access gap analysis, a clinical utility framing document, a trial design review, or a technology assessment.
A rare combination of credentials
Dr. Henry Conter is a practicing Medical Oncologist and Hematologist at William Osler Health System, and the founder of Kesis & Sisters. He trained in Medical Oncology at MD Anderson Cancer Center and holds an MD from McMaster University, an MSc in Health Technology Assessment from the University of Alberta, and an MS in Finance from the University of Houston.
Prior to founding Kesis & Sisters, Dr. Conter spent six years at Hoffmann-La Roche in progressively senior roles spanning Global Medical Director for Thoracic Oncology (Basel), Portfolio Manager in Research & Early Development Oncology, and Strategic Lead for Data-Driven Decision Making in Medical & Regulatory Affairs. He also served as Executive Medical Director for Quality, Patient Safety, and Health System Integration at William Osler Health System.
He has served on Canadian Drug Agency (CDA) pCODR and CCO drug funding committees, and as a Principal Investigator on international real-world oncology registries. He brings this complete vantage point, from bench to boardroom to bedside, to every engagement.
Work with Dr. ConterClinical Appointments
- Medical Oncologist & Hematologist, William Osler Health System 2014 – Present
- Executive Medical Director, Quality & Patient Safety, William Osler 2018 – 2019
Industry Experience
- Global Medical Director, Thoracic Oncology, Hoffmann-La Roche Basel, 2021–22
- Portfolio Manager, R&D Oncology, Hoffmann-La Roche Basel, 2023–24
- Strategic Lead, Data & Regulatory Affairs, Roche Canada 2024–25
Education & Training
- MD, McMaster University
- Medical Oncology Fellowship, MD Anderson Cancer Center
- MSc Health Technology Assessment, University of Alberta
- MS Finance, University of Houston
- BESc Mechanical Engineering, University of Western Ontario
Ready to discuss your strategy?
Whether you are planning a clinical registry, navigating an HTA submission, or building an AI diagnostic tool, we are uniquely positioned to accelerate your timeline and reduce your risk.